Developmental Funds Cancer Center Support Grant (CCSG) Developmental Funds provide UPCI with support to help meet Center- wide and Research Program-specific goals that are developed during planning and evaluation activities that include interactive vision setting.
The specific aims for Developmental Funds are to: 1) Support new faculty recruits who meet one or more of the needs identified in the 2014 UPCI Strategic Plan, 2) Support Pilot Projects that leverage investments already made in UPCI Shared Resources and align with strategic goals pertaining to team science submissions and new UPCI-wide initiatives, 3)Support testing of new services in existing shared resources and development of new shared resources, and 4) Support one CCSG Research Staff Investigator and two CCSG Clinical Staff Investigators. UPCI Director, Nancy E. Davidson, MD, has overall responsibility and authority for allocation of the funds and for ensuring that resulting outcomes are tracked. During the current project period, $1,866,802 in Developmental Funds were used to support: research start-up packages for 10 faculty-level recruits, who conduct research in strategic areas of cancer research and subsequently brought $6,386,881 in new direct grant funding to UPCI; 22 ongoing pilot projects that leveraged recent investments in Shared Resource capabilities in genomics, proteomics, and pre-clinical imaging; development of new technologies and capabilities that led to reconfiguration of and expanded services in several of UPCI?s Shared Resources; and support for one Clinical Staff Investigator (David Bartlett, MD) and two Research Staff Investigators Michael Lotze, MD, and Soldano Ferrone, MD), who contributed to collaboration, team science, and educational enrichment, throughout UPCI. During the upcoming project period, CCSG Developmental Funds will be used support new faculty recruits, pilot projects, Shared Resource development, and Staff Investigators (Drs. Bartlett and Lotze, and new Clinical Staff Investigator Dwight Heron, MD), in order to continue to meet goals developed during UPCI vision setting and strategic planning for the years 2014-2018.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-28
Application #
9114505
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
28
Fiscal Year
2016
Total Cost
$540,774
Indirect Cost
$189,622
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications